Literature DB >> 3831029

Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.

K Nunoki, T Goto, K Satoh, N Taira.   

Abstract

The efficacy of denopamine, an orally active beta 1-adrenoceptor agonist, in improving cardiac failure was assessed in dog heart-lung preparations. Cardiac functions depressed by pentobarbital (118 +/- 28 mg; mean value +/- SD) such that cardiac output and maximum rate of rise of left ventricular pressure (LV dP/dt max) had been reduced by about 35% and 26% of the respective controls were improved by denopamine (10-300 micrograms) in a dose-dependent manner. With 100 micrograms denopamine, almost complete restoration of cardiac performance was attained, associated with a slight increase in heart rate. No arrhythmias were induced by these doses of denopamine. The results warrant clinical trials of denopamine in the treatment of cardiac failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3831029     DOI: 10.1007/bf02073652

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  10 in total

1.  Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62.

Authors:  G Johnsson; L Jordö; P Lundborg; O Rönn; I Welin-Fogelberg; J Wikstrand
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

2.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

3.  Improvement of cardiac performance by AR-L 115 BS, a new cardiotonic drug, in the experimental failing dog heart.

Authors:  T Morita; K Satoh; N Taira
Journal:  Jpn Heart J       Date:  1984-05

4.  Haemodynamic effects of prenalterol in patients with coronary heart disease.

Authors:  I Hutton; R G Murray; R N Boyes; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1980-02

5.  Effects of a cardiotonic agent, TA-064, on isolated canine cerebral, coronary, femoral, mesenteric, and renal arteries.

Authors:  N Ozaki; K Bito; M Kinoshita; S Kawakita
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

6.  Inotropic drugs of the future.

Authors:  H Pouleur; J M Detry; G Mancia
Journal:  Eur J Clin Invest       Date:  1982-12       Impact factor: 4.686

7.  The cardiovascular acitivity of ICI 118,587 a novel beta-adrenoceptor partial agonist [proceedings].

Authors:  J J Barlow; B D Main; J A Moors; A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

8.  Improvement by trapidil of cardiac function of the dog heart-lung preparation depressed by pentobarbital.

Authors:  K Satoh; M Kawada; N Taira
Journal:  Jpn Heart J       Date:  1983-05

9.  Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts.

Authors:  M Kino; Y Hirota; S Yamamoto; K Sawada; M Moriguchi; M Kotaka; S Kubo; K Kawamura
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

10.  Cardiovascular effects of a new positive inotropic agent, (-)-(R)-1-(p-hydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]-ethanol (TA-064) in the anesthetized dog and isolated guinea pig heart.

Authors:  T Nagao; T Ikeo; S Murata; M Sato; H Nakajima
Journal:  Jpn J Pharmacol       Date:  1984-08
  10 in total
  2 in total

1.  On minimum cyclic AMP formation rates associated with positive inotropic effects mediated through beta 1-adrenoceptors in kitten myocardium. Beta 1-specific and non-adrenergic stimulant effects of denopamine.

Authors:  H Lemoine; K J Teng; S J Slee; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

Review 2.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.